Tags: ms + drug company.with.MS

Sort by: Date / Title / URL

1. ScienceDaily: Genes That Affect Responses Of Multiple Sclerosis Patients To Copaxone Identified
   In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
   11-10-2007 to copaxone, drug company, drugs, genetics, ms, multiple sclerosis, treatment by admin
2. Momenta Pharmaceuticals Inc (MNTA.O) Full Description | Stocks | Reuters.com
   Momenta's second generic product candidate is M356, a technology-enabled generic version of Copaxone (glatiramer acetate), a complex drug consisting of a mixture of polypeptide chains. Copaxone is indicated for the reduction of the frequency of relapses
   13-08-2007 to copaxone, drug company, drugs, ms, multiple sclerosis, rrms by admin
3. Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
   The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
   03-08-2007 to betaseron, drug company, drugs, interferon, ms, multiple sclerosis, newly diagnosed, study, treatment by admin
4. UPDATE 3-Biogen tops 2nd-qtr estimates, boosts 2007 outlook | Markets News | Reuters.com
   Biogen Idec Inc. (BIIB.O: Quote, Profile , Research) reported second-quarter earnings that topped expectations on Tuesday, helped by higher sales of its drugs for multiple sclerosis and cancer and a lower tax rate.
   25-07-2007 to avonex, drug company, drugs, ms, multiple sclerosis, rituxan, tysabri by admin
5. PharmaLive: BioMS Medical's Relapsing-remitting Multiple Sclerosis Trial Receives Positive Review from Data Safety Monitoring Board
   The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS.
   25-07-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, relapsing remitting, rrms by admin
6. GW Pharma forced to hold back on cannabis treatment - Independent Online Edition > Business News
   Savitex, an oral spray developed by the drugs company GW Pharmaceuticals, is now unlikely to gain regulatory approval in this country until 2009 despite recently winning full regulatory approval in Canada
   22-07-2007 to drug company, drugs, marijuana, ms, multiple sclerosis, sativex, uk by admin
7. PharmaLive: Acorda Therapeutics Begins Second Phase 3 Clinical Trial of Fampridine-SR in Multiple Sclerosis
   The MS-F204 study, which is conducted under a Special Protocol Assessment (SPA) issued by the Food and Drug Administration (FDA), will evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with MS.
   07-06-2007 to clinical trial, drug company, drugs, fampridine, ms, multiple sclerosis by admin
8. BioMS Medical initiates enrollment in pivotal U.S. phase III multiple sclerosis trial
   the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis
   07-06-2007 to clinical trial, drug company, drugs, mbp8298, ms, multiple sclerosis, spms by admin
9. MS victims denied vital drug due to the high cost : thewest.com.au
   Under a Pharmaceutical Benefits Scheme ruling, people with MS will miss out on the drug, Tysabri, unless they can pay more than $30,000 a year when it becomes available in Australia in a few months.
   30-05-2007 to australia, drug company, drugs, ms, multiple sclerosis, tysabri by admin
10. NORD - National Organization for Rare Disorders, Inc.
    Since 1987, NORD has administered programs to assist uninsured or under-insured individuals in securing life-saving or life-sustaining medications.
    21-05-2007 to drug company, drugs, ms, multiple sclerosis by admin
11. Welcome to Rebif.com - Multiple Sclerosis (MS) Treatment Information
    13-06-2006 to drug company, drugs, interferon, ms, multiple sclerosis, rebif, relapsing remitting, rrms, treatment by admin

First / Previous / Next / Last / Page 1 of 1